PhaseV, a developer of software and machine learning for clinical trial optimisation, announced on Monday that it has partnered with Alimentiv Inc, a gastrointestinal (GI) contract research organisation.
The partnership is aimed at supporting the optimal design and implementation of advanced adaptive clinical trials for a range of GI conditions. These trials will focus on inflammatory bowel disease (IBD), coeliac disease, eosinophilic gastrointestinal disease (EGID) and other related disorders.
According to PhaseV, the partnership has the potential to accelerate the development of new GI therapies by using adaptive trial methodologies that improve efficiency and results for patients facing these challenging conditions.
Medivir secures European patent for fostrox and lenvatinib combination in liver cancer treatment
Workflow Services completes one-year pilot and expands Colorectal Cancer Screening Education Program
RedHill Biopharma to submit Talicia for UK marketing authorisation
bioMérieux receives FDA clearance for VITEK COMPACT PRO to combat antimicrobial resistance
BiBBInstruments successfully demonstrates EndoDrill GI in live biopsy procedure
Evommune enrols first patient in EVO301 Phase 2 trial
Telix Pharmaceuticals' Illuccix approved in Brazil
Physiomics secures GBP102,000 contract with UK biotech for ADC therapy development
Revelation Biosciences reports Gemini's anti-inflammatory potential in PBMC study
AstraZeneca secures EU approval for Imfinzi in limited-stage small cell lung cancer